| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 |
| Sales | 5,060 | 18,160 | 27,120 | 29,880 | 20,100 |
| Sales Growth | -72.14% | -33.04% | -9.24% | +48.66% | +265.45% |
| Net Income | -20,130 | -16,800 | -26,240 | -31,850 | -21,100 |
| Net Income Growth | -19.82% | +35.98% | +17.61% | -50.95% | -43.83% |
(OGXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Oncogenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011 or custirsen the lead candidate currently completing three Phase 3 clinical studies in prostate and lung cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 2 clinical trials in bladder, lung, pancreas and prostate cancers; and OGX-225 is currently in pre-clinical development.